Elite in Osteogenesis Imperfecta

Francis H. Glorieux

Montreal, QC, CA 
Elite in Osteogenesis Imperfecta
Montreal, QC, CA 
OverviewLocationsClinical Research

Overview

Francis Glorieux practices in Montreal, Canada. Mr. Glorieux is rated as an Elite expert by MediFind in the treatment of Osteogenesis Imperfecta. His top areas of expertise are Osteogenesis Imperfecta, X-Linked Hypophosphatemia, Rickets, Hypophosphatemia, and Osteotomy.

His clinical research consists of co-authoring 111 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 77 articles and participated in 2 clinical trials in the study of Osteogenesis Imperfecta.

Gender
Male

Locations

Montreal, QC H3A0G4, Canada
Other Locations
Montreal, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Cross-Linked Collagen Peptides as a Urinary Biomarker of OI Pathobiology
Cross-Linked Collagen Peptides as a Urinary Biomarker of OI Pathobiology
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2024
A Randomized, Open-Label, Phase 3 Study to Assess the Efficacy and Safety of KRN23 Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With X Linked Hypophosphatemia (XLH)
A Randomized, Open-Label, Phase 3 Study to Assess the Efficacy and Safety of KRN23 Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With X Linked Hypophosphatemia (XLH)
Enrollment Status: Completed
Publish Date: August 29, 2024
Intervention Type: Drug, Biological
Study Phase: Phase 3
A Phase 2b, Multicentre, Multinational, Double-blind, Dose-finding Study, Incorporating an Open Label Substudy, in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With Setrusumab (BPS804)
A Phase 2b, Multicentre, Multinational, Double-blind, Dose-finding Study, Incorporating an Open Label Substudy, in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With Setrusumab (BPS804)
Enrollment Status: Completed
Publish Date: July 05, 2023
Intervention Type: Dietary supplement, Drug
Study Phase: Phase 2
View 2 Less Clinical Trials

111 Total Publications

Bone microstructural and strength changes over one year in children with osteogenesis imperfecta are comparable to age- and sex-matched healthy controls.
Bone microstructural and strength changes over one year in children with osteogenesis imperfecta are comparable to age- and sex-matched healthy controls.
Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
Published: February 15, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Glorieux's expertise for a condition
ConditionClose
View All 17 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile